Your SlideShare is downloading. ×
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Fda gutierrez slides[3]
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Fda gutierrez slides[3]

428

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
428
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
23
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. FDA Perspective: How Different Constituencies Can Work Together BetterThe 2012 DiabetesMine Innovation Summit Friday, November16, 2012 Palo Alto, CA Alberto Gutierrez, Ph.D. Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health Food and Drug Administration
  • 2. Diabetes•  More than 18 million children and adults in the U.S. have been diagnosed with diabetes•  Diabetes healthcare costs in the U.S. surpass $170 billion dollars•  Better management of this disease leads to improved outcomes for patients•  Novel therapies and technologies promise to help patients better manage their disease and improve the quality of their lives
  • 3. Medical Device Innovation Pathway 2.0 New FDA initiative for medical devices Shorten the time and cost to market for innovative (and other) medical devicesTransform how FDA and innovators work together
  • 4. Innovation Pathway 2.0Application Process Collaboration Phase Clinical Trials Phase Market Approval FDA Conference Center IT Tools
  • 5. Blood Glucose Meters•  Current accuracy standard (+/-20%) criticized as too broad•  Call for tighter accuracy standards for meters used in healthcare facilities and at home•  FDA held a Public meeting in March 2010 – input gained from clinical community and patients•  FDA working on new guidance / standards to achieve: •  Clinically appropriate (yet achievable) accuracy standards •  Study designs that better reflect actual use •  Labeling and human factors improvements Goal: Safer, more accurate devices for patients with continued availability to for home and clinical use
  • 6. Continuous Glucose Monitors (CGMs)•  CGMs are home use devices that continuously measure glucose in interstitial fluid•  Have demonstrated benefit for the patients that use them•  Challenges remain: •  Sensor accuracy •  Sensor Biofouling •  Differences between interstitial fluid and blood glucose concentrations •  Signal dropout•  FDA has reached out to Industry to discuss ways to improve sensor technology•  Multiple new generation sensors in development by industry – promise to provide incremental improvements in performance over the next several years•  Future – replacement of blood monitoring?
  • 7. Data management•  Current efforts in glucose/insulin data standards development•  Needs: •  Easy data interpretation/standard data format and metrics (esp. for CGM data) •  Consolidation of software/applications •  Easier/faster download capabilities – improved patient interaction with healthcare professionals•  IDC/Helmsley Trust study•  FDA supports standardization efforts in this area - Promises to lead to better patient experience
  • 8. Remote monitoring•  Glucose meter and CGM device accessories for remote monitoring being developed•  Touted for nighttime monitoring (e.g., for pediatric patients)•  Cloud-based monitoring•  Tele-medicine•  Data security/reliability are essential•  Promise as a safety tool to enable faster clinical studies, faster introduction of innovative devices to market
  • 9. Mobile Applications•  Movement toward consolidation of patient devices/interfaces (e.g., CGM, cell phone, glucose meter, insulin pump)•  Security, hacking – specialized communication protocols essential•  Android vs. Apple OS•  FDA is working with industry on requirements/process for market entry, upgrades, etc.•  Promises to be more convenient for patients
  • 10. Artificial Pancreas•  Development of an Artificial Pancreas will improve outcomes for people with diabetes•  FDA changes/updates •  Now reviewed in the Office of In Vitro Diagnostics •  Consolidation of review team – efficiency of review process •  Continued focus on interaction with investigators, promotion of new devices and studies•  Artificial Pancreas Guidance •  Drafts published June and December 2011 •  Currently being finalized for publication soon•  Outpatient studies beginning for closed loop devices•  Feedback and ideas are welcome
  • 11. Hospital Glucose Sensors•  Intended to be used in ICU settings for continuous or near-continuous measurement of glucose to aid in glycemic control protocols•  Multiple products in development •  Venous or arterial blood •  Interstitial fluid•  FDA Public Meeting – June 25, 2012 •  Value in trends •  Discussion on dosing/safety •  Study design considerations•  Broader use than diabetes, but novel technologies that result promise to advance glucose monitoring devices
  • 12. Thank you! alberto.gutierrez@fda.hhs.gov

×